Financing - September 22, 2014
Recipharm secures financing
The company has entered a new five-year SEK 1 500 million loan facility with three of the largest banks in Scandinavia for continued growth. The revolving credit facility of SEK 1 500 million is signed with DNB, Handelsbanken and Swedbank and will serve as an additional resource to facilitate future expansion plans set in place for the business, […]
Financing - September 18, 2014
Pulmologix raises EUR 9.6 million
Swedish Pulmologix AB has closed a series B financing of EUR 9.6 million to develop a new oral non-steroidal anti-asthmatic (ONSA) for the treatment of early onset allergic asthma. According to a press release, the financing was led by Novo Seeds, the seed fund of Novo A/S, and Sunstone Capital of Denmark. Previous investors Forbion Capital Partners […]
Financing - September 16, 2014
New owner for Diamyd Medical
Diamyd Medical is extending its collaboration with Protein Sciences regarding the development of diabetes treatment. Following the new agreement the American firm becomes one of the larger share holders of Diamyd. Diamyd Medical and Protein Sciences Corporation have announced that Protein Sciences has broadened its commitment to diabetes and become a strategic and significant shareholder […]
Financing - September 1, 2014
Orexo completes private placement of SEK 346.5 million
Orexo AB has announced that its private placement of 2,493,046 Orexo shares has been completed. The placement included all Orexo shares held in treasury by the company in addition to newly issued shares. The price of SEK 139 per share was determined through a book-building procedure, resulting in total cash proceeds of approximately SEK 346.5m before […]
Financing - August 25, 2014
Swedish biotech firm announces rights issue
The Board of Ellen AB has decided to to carry out a new rights issue which will give the company a capital injection of about SEK 6.9 million. The rights issue means that individuals registered as shareholders in Ellen AB on record day 3 September 2014 will be granted one subscription right for every current share. Seven subscription […]
Financing - August 20, 2014
Vigmed sets eyes on Nasdaq OMX Small Cap
The board of Vigmed has initiated a process to prepare the company for a change of venue for the company’s shares from NASDAQ OMX First North to NASDAQ OMX Stockholm Small Cap. Vigmed states that it is a natural step considering the anticipated growth linked to the fact that the company now has started selling its […]
